公开(公告)号：US11492346B2

公开(公告)日：2022-11-08

申请号：US16902515

申请日：2020-06-16

Applicant: Pfizer Inc. ,  CTXT PTY LTD

Inventor： Ylva Elisabet Bergman Bozikis ,  Michelle Ang Camerino ,  Pei-Pei Kung ,  Paul Anthony Stupple ,  Scott Channing Sutton

IPC: C07D413/06 ,  A61P35/04 ,  A61K45/06

Abstract: The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein Ring A, R1-R8, and n are defined herein. The novel benzisoxazole sulfonamide derivatives are useful in the treatment of abnormal cell growth, such as cancer, in patients. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in patients.

公开(公告)号：US10570121B2

公开(公告)日：2020-02-25

申请号：US16156304

申请日：2018-10-10

Applicant: Pfizer Inc.

Inventor： Michael Raymond Collins ,  Robert Steven Kania ,  Robert Arnold Kumpf ,  Pei-Pei Kung ,  Daniel Tyler Richter ,  Scott Channing Sutton ,  Martin James Wythes

IPC: C07D401/06 ,  C07B59/00 ,  A61K31/4725 ,  C07D405/14 ,  C07D401/14 ,  C07D413/14 ,  C07D409/14

Abstract: This invention relates to compounds of general formula (I) in which R1, R2, R3, R4, L, X and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

公开(公告)号：US20150361067A1

公开(公告)日：2015-12-17

申请号：US14740439

申请日：2015-06-16

Applicant: PFIZER INC.

Inventor： Michael Raymond Collins ,  Robert Steven Kania ,  Robert Arnold Kumpf ,  Pei-Pei Kung ,  Daniel Tyler Richter ,  Scott Channing Sutton ,  Martin James Wythes

IPC: C07D401/06 ,  C07D409/14 ,  C07D413/14 ,  C07D405/14 ,  C07D401/14

CPC classification number: C07D405/14 ,  C07B59/002 ,  C07B2200/05 ,  C07D401/06 ,  C07D401/14 ,  C07D409/14 ,  C07D413/14

Abstract: This invention relates to compounds of general formula (I) in which R1, R2, R3, R4, L, X and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

Abstract translation: 本发明涉及其中R1，R2，R3，R4，L，X和Z如本文所定义的通式（I）化合物及其药学上可接受的盐，涉及包含这些化合物和盐的药物组合物，以及方法 使用这些化合物，盐和组合物来治疗异常细胞生长，包括癌症。

公开(公告)号：US20150239842A1

公开(公告)日：2015-08-27

申请号：US14430799

申请日：2013-09-16

Applicant: PFIZER INC.

Inventor： Martin Paul Edwards ,  Robert Arnold Kumpf ,  Pei-Pei Kung ,  Indrawan James Mcalpine ,  Eugene Yuanjin Rui ,  Scott Channing Sutton ,  John Howard Tatlock ,  Martin James Wythes

IPC: C07D213/64 ,  C07D487/08 ,  C07D491/08 ,  C07D405/14 ,  C07D413/14 ,  C07D401/12 ,  C07D401/14

CPC classification number: C07D401/14 ,  C07D213/64 ,  C07D401/12 ,  C07D405/14 ,  C07D407/14 ,  C07D409/14 ,  C07D413/14 ,  C07D487/08 ,  C07D491/08

Abstract: This invention relates to compounds of general formula (I), in which R1, R2, R6, U, V, W, X, Y and Z are as defined herein, and the pharmaceutically acceptable salts thereof, pharmaceutical compositions containing such compounds and salts, and to methods of using such compounds, salts and compositions.

Abstract translation: 本发明涉及通式（I）的化合物，其中R1，R2，R6，U，V，W，X，Y和Z如本文所定义，及其药学上可接受的盐，含有这些化合物和盐的药物组合物 以及使用这些化合物，盐和组合物的方法。

公开(公告)号：US20190040055A1

公开(公告)日：2019-02-07

申请号：US16157618

申请日：2018-10-11

Applicant: Pfizer Inc.

Inventor： Aaron Craig Burns ,  Michael Raymond Collins ,  Samantha Elizabeth Greasley ,  Robert Louis Hoffman ,  Peter Qinhua Huang ,  Robert Steven Kania ,  Pei-Pei Kung ,  Maria Angelica Linton ,  Lakshmi Sourirajan Narasimhan ,  Paul Francis Richardson ,  Daniel Tyler Richter ,  Graham Smith

IPC: C07D417/14 ,  C07D417/08 ,  C07D277/46 ,  A61K45/06 ,  A61K31/427 ,  A61K31/501 ,  A61K31/444 ,  A61K31/4439 ,  C07D401/14 ,  A61K31/506

Abstract: The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein A, L, D, R1-R15, w, x, y, and z are defined herein. The novel cycloalkyl-linked diheterocycle derivatives that are useful in the treatment of abnormal cell growth, such as cancer, in mammals. The present invention also relates to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.

公开(公告)号：US20160376254A1

公开(公告)日：2016-12-29

申请号：US15262230

申请日：2016-09-12

Applicant: Pfizer Inc.

Inventor： Michael Raymond COLLINS ,  Robert Steven Kania ,  Robert Arnold Kumpf ,  Pei-Pei Kung ,  Daniel Tyler Richter ,  Scott Channing Sutton ,  Martin James Wythes

IPC: C07D401/06 ,  C07D409/14 ,  C07D413/14 ,  C07B59/00 ,  C07D405/14 ,  C07D401/14

CPC classification number: C07D405/14 ,  C07B59/002 ,  C07B2200/05 ,  C07D401/06 ,  C07D401/14 ,  C07D409/14 ,  C07D413/14

Abstract: This invention relates to compounds of general formula (I) in which R1, R2, R3, R4, L, X and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

Abstract translation: 其中R 1，R 2，R 3，R 4，L，X和Z如本文所定义，及其药学上可接受的盐，包含这些化合物和盐的药物组合物，以及使用这些化合物，盐和组合物进行治疗的方法 的细胞生长异常，包括癌症。

公开(公告)号：US09481666B2

公开(公告)日：2016-11-01

申请号：US14740439

申请日：2015-06-16

Applicant: PFIZER INC.

Inventor： Robert Steven Kania ,  Robert Arnold Kumpf ,  Pei-Pei Kung ,  Scott Channing Sutton ,  Martin James Wythes

IPC: C07D401/06 ,  C07D401/14 ,  A61K31/44 ,  A61K31/47 ,  C07D405/14 ,  C07D413/14 ,  C07D409/14

CPC classification number: C07D405/14 ,  C07B59/002 ,  C07B2200/05 ,  C07D401/06 ,  C07D401/14 ,  C07D409/14 ,  C07D413/14

Abstract: This invention relates to compounds of general formula (I) in which R1, R2, R3, R4, L, X and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

Abstract translation: 本发明涉及其中R1，R2，R3，R4，L，X和Z如本文所定义的通式（I）化合物及其药学上可接受的盐，涉及包含这些化合物和盐的药物组合物，以及方法 使用这些化合物，盐和组合物来治疗异常细胞生长，包括癌症。

公开(公告)号：US20250122183A1

公开(公告)日：2025-04-17

申请号：US18903849

申请日：2024-10-01

Applicant: Pfizer Inc. ,  CTXT PTY LTD

Inventor： Alexander Burtea ,  Michael Raymond Collins ,  Matthew L. Del Bel ,  Samantha Elizabeth Greasley ,  Eric Johnson ,  Ted William Johnson ,  Robert Arnold Kumpf ,  Pei-Pei Kung ,  Timothy Patrick Montgomery ,  Sacha Ninkovic ,  Gwenaella Christine Rescourio ,  Paul Francis Richardson ,  Stephanie Anne Scales ,  Scott Channing Sutton

IPC: C07D413/14 ,  A61K31/423 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/501 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5377 ,  C07D413/12 ,  C07D471/04

Abstract: The present invention relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, wherein Ring A, Ring B, R1—R16, n and p are defined herein. The novel nitrogen-linked benzisoxazole sulfonamide derivatives are useful in the treatment of abnormal cell growth, such as cancer, in patients. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth, such as cancer, in patients.

公开(公告)号：US20220251075A1

公开(公告)日：2022-08-11

申请号：US17620188

申请日：2020-06-17

Applicant: Pfizer Inc. ,  CTXT PTY LTD

Inventor： Oleg Brodsky ,  Samantha Elizabeth Greasley ,  Robert Louis Hoffman ,  Pei-Pei Kung ,  Paul Francis Richardson ,  Paul Anthony Stupple

IPC: C07D413/14 ,  C07D413/06

Abstract: The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein Ring A, Y, R1-R8, m, n and p are defined herein. The novel cycloalkyl and heterocycloalkyl benzisoxazole sulfonamide derivatives are useful in the treatment of abnormal cell growth, such as cancer, in patients. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in patients.

公开(公告)号：US20170298048A1

公开(公告)日：2017-10-19

申请号：US15635648

申请日：2017-06-28

Applicant: Pfizer Inc.

Inventor： Michael Raymond Collins ,  Robert Steven Kania ,  Robert Arnold Kumpf ,  Pei-Pei Kung ,  Daniel Tyler Richter ,  Scott Channing Sutton ,  Martin James Wythes

IPC: C07D405/14 ,  C07D401/06 ,  C07D401/14 ,  C07D409/14

CPC classification number: C07D405/14 ,  C07B59/002 ,  C07B2200/05 ,  C07D401/06 ,  C07D401/14 ,  C07D409/14 ,  C07D413/14

Abstract: This invention relates to compounds of general formula (I) in which R1, R2, R3, R4, L, X and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.